As part of a push to align the names of Australia’s medicinal ingredients with names used internationally, Australia’s Therapeutics Goods Administration (TGA) has been transitioning more than 220 ingredient names as part of a process that will last until 1 May 2020.
TGA acknowledged that over the years, some of the ingredient names in Australia have become out of date. And although some of the changes are minor spelling corrections (e.g., Amoxycillin to amoxicillin), others are more significant (e.g., Colaspase to asparaginase or Salcatonin to calcitonin salmon).
For the products seeing these more significant changes, TGA will require updates to the medicine labels with both the old and new ingredient name included for an additional three years after the end of the transition period (until 2023) to help consumers and health professionals become familiar with the new name.
“For example, medicines containing lignocaine will need to be dual labelled as ‘lidocaine (lignocaine),’” TGA said. Sponsors of the medicines have known that the name changes were coming since 2016…